Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint. I am aware this is the third time this month I have made this point.
On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion.
Regional question, dated March 2026, because everything in this category expires.
The position differs between the jurisdictions people usually treat as one, and the differences are not marginal. I have set out what I can verify for my own region from primary sources rather than summaries.
If you can confirm or contradict this for yours, please date the answer.
Following, with nothing to contribute beyond having asked the same thing elsewhere.
The most useful contribution is a link to the current official page with the date you accessed it. That survives; a paraphrase does not.
The variance between people here is larger than the effect being discussed.
Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.
Happy to be the one who is wrong here if it settles the question.
Post #4 describes the usual case. This is about the unusual one.
Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.
Adding the caveat now so it does not have to be extracted later.
Members outside these two jurisdictions reading this thread should note that none of it transfers, including the parts that sound general.
Correcting an out-of-date claim in this subcategory with a source and a date is more valuable than a new topic on the same question.
A weak preference rather than a position.
Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.
I am aware this is the third time this month I have made this point.
Post #11 is right about the mechanism and I think understates the practical bit.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.
I would want to see it done twice before believing it once.
I had written a reply contradicting post #11 and deleted it. Here is what survived.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
The short version is the first sentence; the rest is why.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the UK & Ireland category
MHRA positions, NHS pathways, private prescriptions, and Irish differences. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
|
+3 | 7 | 357 | 3mo |
|
Second pass at: Pharmacy supply in the UK and the questions you will be asked
Second pass at: Pharmacy supply in the UK and the questions you will be asked Writing it up because I had to work it out twice and would rather nobody else did. Asking about Pharmacy supply on behalf of the…
|
+46 | 53 | 14k | 12mo |
|
Private prescribing in the UK: what is actually involved
On the subject in the title: Private prescribing in the UK: what is actually involved Working notes rather than a conclusion. The question about private prescribing that I actually want answered is the second…
|
+66 | 76 | 46k | 14h |
|
MHRA statements, read directly
MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each…
|
+93 | 101 | 2.2k | 5mo |
|
Irish differences from the UK position
Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Trying to establish the boundary conditions on irish differences. The general…
|
+62 | 66 | 993 | 21mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since…
|
+28 | 32 | 640 | 13mo |
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…
|
+62 | 67 | 2.1k | 6mo |
|
Irish differences from the UK position — what changed since
Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Irish differences is wrong? I ask…
|
+8 | 12 | 782 | 1d |
|
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A narrow question about NHS criteria, deliberately…
|
+11 | 15 | 11k | 9mo |
|
Enforcement priorities versus written rules — does this still hold?
Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says,…
|
+36 | 40 | 37k | 11mo |